Drugs / HNC1058
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05803850 | Mar 2023 → Feb 2024 | idiopathic pulmonary fibrosis | Guangzhou Henovcom Bioscience Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HNC1058 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05803850 ↗ |
| Route | Oral | “single ascending oral doses” NCT05803850 ↗ |